News

The agreement, which includes global marketing rights beginning at the close of the Torino 2006 Olympic Winter Games, involves Johnson & Johnson's consumer products, over-the-counter pharmaceuticals and medical

The agreement covers three abbreviated new drug applications (ANDAs) Spectrum has already had approved by the FDA, and a further nine currently under review. The contract also covers

Opatanol (olopatadine hydrochloride) was first authorized in the European Union in May 2002 as eye drops for the treatment of ocular signs and symptoms of seasonal allergic conjunctivitis.

The drug is specifically indicated for pediatric patients who have relapsed or are refractory to at least two prior regimens. The positive opinion must now be converted into

The patent on Glaxo’s Flonase expired in November 2005, allowing Roxane, a subsidiary of Boehringer Ingelheim, to apply for approval of its generic product containing the same active

As a part of this program, BioSystems International will conduct biomarker discovery using its proprietary technology platform, whilst AstraZeneca will provide clinical samples and funding. BioSystems will retain

All of Sepracor’s patents and patent applications in the US regarding the antihistamine are now licensed to UCB, who will have to pay royalties to Sepracor on US

The FDA’s decision means that Mylan’s application is in order and the product will be approved pending patent expiry or legal issues surrounding the original drug. The drugs

The company designed two separate studies, the first of which was a single dose, three-way crossover study of 156 participants evaluating a modified formulation (MF) of Niaspan designed